Key result
Five dabigatran-specific assays showed variable agreement with the reference Hemoclot Thrombin Inhibitors assay, with modest Bland-Altman bias ranging from -17.3 to 4.0 ng/mL.
Why the study?
Do five specific assays provide reliable assessment of dabigatran plasma levels compared to the Hemoclot Thrombin Inhibitors assay in patient plasma samples?
Cross-Sectional (n=295)
Yes
Do five specific assays provide reliable assessment of dabigatran plasma levels compared to the Hemoclot Thrombin Inhibitors assay in patient plasma samples?
Five commercially available dabigatran-specific assays provide reliable assessment of dabigatran plasma levels, though with varying limits of detection and quantification.
Answers are grounded in this paper and cite their sources.
Variable agreement among dabigatran assays warrants interpretive caution; leaves open standardization needs in larger studies.
INTRODUCTION: Several specific assays are commercially available to determine dabigatran anticoagulant activity. Aims of this multicenter and multiplatform study were to compare five methods for dabigatran measurement and investigate their performances in the low concentration range. METHODS: Dabigatran levels were analyzed in 295 plasma samples from patients enrolled in the START-Laboratory Register by the following methods using dedicated calibrators and controls: STA-ECA II (Diagnostica Stago), standard and low range Hemoclot Thrombin Inhibitors (Hyphen BioMed), Direct Thrombin Inhibitor Assay (Instrumentation Laboratory), Direct Thrombin Inhibitor Assay (Siemens), Technoclot DTI (Technoclone). RESULTS: Methods showed variable agreement with the Hemoclot Thrombin Inhibitors assay used as reference test, with modest under- or overestimations (Bland-Altman bias from -17.3 to 4.0 ng/mL). Limits of detection and quantification varied depending on the assay (4-52 and 7-82 ng/mL, respectively). Between-run precision and accuracy were good for all methods for both quality control levels. Assay's repeatability assessed at very low dabigatran concentrations (from 10 to 60 ng/mL) was also acceptable, variability generally increased at lower drug levels. CONCLUSION: The five dabigatran-specific assays evaluated in this study provided reliable assessment of dabigatran plasma levels, although showing different performances.
No takes yet. Share an insight, caveat, or question.
Cini et al. (2018) conducted a cross-sectional in Patients taking dabigatran (n=295). Five specific assays for dabigatran plasma concentrations vs. Hemoclot Thrombin Inhibitors assay (reference test) was evaluated on Agreement with the reference test (Bland-Altman bias) (Bland-Altman bias from -17.3 to 4.0 ng/mL). Five dabigatran-specific assays showed variable agreement with the reference Hemoclot Thrombin Inhibitors assay, with modest Bland-Altman bias ranging from -17.3 to 4.0 ng/mL.
Synapse has enriched 10 related papers. Consider them for comparative context: